Loading...
XASX
4DX
Market cap627mUSD
Dec 05, Last price  
1.90AUD
1D
3.26%
1Q
22.58%
IPO
387.18%
Name

4DMedical Ltd

Chart & Performance

D1W1MN
XASX:4DX chart
P/E
P/S
261.17
EPS
Div Yield, %
Shrs. gr., 5y
16.59%
Rev. gr., 5y
40.12%
Revenues
4m
+1,230.44%
252,811350,8901,925789,259695,0011,232,501216,9781,054,300282,1813,754,256
Net income
-36m
L+14.36%
-139,029-796,268-3,973,937-3,936,980-6,491,005-21,975,379-21,420,531-24,592,876-31,459,798-35,978,672
CFO
-31m
L+36.26%
-40,940-703,000-2,158,364-3,378,717-5,778,913-7,650,348-14,520,004-25,269,278-22,652,694-30,866,882

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

4DMedical Limited operates as a medical technology company in Australia and the United States. It commercializes XV Technology, a four-dimensional lung imaging technology. The company also offers software as a service delivery model; XV lung ventilation analysis software; Permetium, a preclinical imaging system which quantify regional changes in pulmonary function; and AccuVent 200, a small animal ventilator. The company was incorporated in 2012 and is based in Carlton, Australia.
IPO date
Aug 07, 2020
Employees
131
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT